Inter-ethnic differences in xenobiotic metabolism.

The aim of safety assurance procedures is to determine a level of intake (the acceptable daily intake (ADI) or tolerable daily intake (TDI)) that is without adverse health effects in the human population. The majority of studies on inter-ethnic differences in xenobiotic metabolism have concentrated in the incidence of expression of the poor metaboliser phenotype for a number of drug metabolising enzymes. Such ethnic differences can result in different incidences of individuals at higher risk, but this would not affect the safety assurance/risk assessment outcome unless poor metaboliser status was not recognised in the database used for the initial assessment and calculation of ADI or TDI. Of far greater importance are ethnic differences which result in population differences in the mean values, and/or the extent of variability within the population, for key kinetic parameters such as the internal dose or area under the plasma concentration time curve (AUC). There are few studies on inter-ethnic differences in sensitivity and most of these relate to in vivo differences for therapeutic/pharmacological agents, so that the reported data reflect both kinetic and dynamic variability. Inter-ethnic differences are limited in extent and well within the uncertainty factor of 10 used for human variability.

[1]  B. Henderson,et al.  Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. , 1994, Journal of the National Cancer Institute.

[2]  P. Meredith,et al.  Racial differences in drug responses--a comparative study of trimazosin and alpha 1-adrenoceptor responses in normotensive Caucasians and West Africans. , 1986, British journal of clinical pharmacology.

[3]  J. Moncrieff,et al.  Non-correlation between Debrisoquine and Metoprolol Polymorphisms in the Venda , 1989, Human toxicology.

[4]  F. Flores-Murrieta,et al.  Pharmacokinetics of Oral Nifedipine in Different Populations , 1993, Journal of clinical pharmacology.

[5]  B D Kahan,et al.  Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability , 1992, Clinical pharmacology and therapeutics.

[6]  A G Renwick,et al.  The influences of dose and ethnic origins on the pharmacokinetics of nifedipine , 1993, Clinical pharmacology and therapeutics.

[7]  R. Rubin,et al.  Haloperidol and prolactin concentrations in Asians and Caucasians. , 1988, Journal of clinical psychopharmacology.

[8]  M. Ingelman-Sundberg,et al.  Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancer. , 1992, Pharmacogenetics.

[9]  W. Satariano,et al.  Racial differences in cancer incidence: The significance of age‐specific patterns , 1988, Cancer.

[10]  B. Ketterer Effects of genetic polymorphism and enzyme induction in the glutathione S-transferase family on chemical safety and risk assessment. , 1996, Environmental toxicology and pharmacology.

[11]  V. Mathan,et al.  Geographic differences in digoxin inactivation, a metabolic activity of the human anaerobic gut flora. , 1989, Gut.

[12]  J. Miners,et al.  Drug glucuronidation in humans. , 1991, Pharmacology & therapeutics.

[13]  A. Renwick Data-derived safety factors for the evaluation of food additives and environmental contaminants. , 1993, Food additives and contaminants.

[14]  D. Jacobs,et al.  Racial differences in serum cotinine levels among smokers in the Coronary Artery Risk Development in (Young) Adults study. , 1990, American journal of public health.

[15]  L Aarons Population approaches/sparse data analysis for human variability in kinetics and dynamics. , 1996, Environmental toxicology and pharmacology.

[16]  M. Eichelbaum,et al.  Dissociation of co‐regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians , 1985, Clinical pharmacology and therapeutics.

[17]  G. Wilkinson,et al.  Frequency of impaired mephenytoin 4'-hydroxylation in an Indian population. , 1990, British journal of clinical pharmacology.

[18]  B. Pasternack,et al.  Expression of the CYP1A1 gene in peripheral lymphocytes as a marker of exposure to creosote in railroad workers. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[19]  A. S. Gross,et al.  The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects. , 1990, Pharmacology & therapeutics.

[20]  R. Branch,et al.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.

[21]  L F Prescott,et al.  Inter-subject and ethnic differences in paracetamol metabolism. , 1986, British journal of clinical pharmacology.

[22]  Margaret Wood,et al.  Ethnic differences in response to morphine , 1993 .

[23]  F. Gonzalez,et al.  Molecular genetics of the P-450 superfamily. , 1990, Pharmacology & therapeutics.

[24]  A. Renwick,et al.  Ethnic differences in the pharmacokinetics of oral nifedipine. , 1991, British journal of clinical pharmacology.

[25]  T. Ishizaki,et al.  Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese , 1989, Clinical pharmacology and therapeutics.

[26]  C. Pui,et al.  Thiopurine methyltransferase activity in American white subjects and black subjects , 1994, Clinical pharmacology and therapeutics.

[27]  W. Kalow Interethnic variation of drug metabolism. , 1991, Trends in pharmacological sciences.

[28]  W. Kalow Pharmacogenetics of drug metabolism , 1980 .

[29]  W. Kalow,et al.  Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians. , 1985, British journal of clinical pharmacology.

[30]  E. Taioli,et al.  Relationship between genotype and function of the human CYP1A1 gene. , 1993, Journal of toxicology and environmental health.

[31]  O. Lockridge Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. , 1990, Pharmacology & therapeutics.

[32]  D. Evans,et al.  Genetic polymorphism and interethnic variability of plasma paroxonase activity. , 1976, Journal of medical genetics.

[33]  M. Relling,et al.  Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. , 1993, The Journal of clinical investigation.

[34]  R. Branch,et al.  Genetic polymorphism of S-mephenytoin hydroxylation. , 1989, Pharmacology & therapeutics.

[35]  A. Renwick,et al.  Factors affecting the absolute bioavailability of nifedipine. , 1995, British journal of clinical pharmacology.

[36]  D. W. Robin,et al.  Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. , 1996, British journal of clinical pharmacology.

[37]  M. Relling,et al.  Racial and gender differences in N‐acetyltransferase, xanthine oxidase, and CYP1A2 * activities , 1992, Clinical pharmacology and therapeutics.

[38]  G. Tucker,et al.  Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. , 1992, Pharmacogenetics.

[39]  G R Wilkinson,et al.  Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. , 1989, The New England journal of medicine.

[40]  W. Kalow,et al.  Thiopurine S‐methyltransferase activity in a Chinese population , 1993, Clinical pharmacology and therapeutics.

[41]  R. Hoover,et al.  Lung cancer, race, and a CYP1A1 genetic polymorphism. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[42]  Honghao Zhou,et al.  Ethnic Differences in Drug Disposition and Responsiveness , 1991, Clinical pharmacokinetics.

[43]  A. Renwick,et al.  Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. , 1995, British journal of clinical pharmacology.